Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder

Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder

Bibliographic Details
Main Authors:	Hacohen, Y, Palace, J
Format:	Journal article
Language:	English
Published:	American Academy of Neurology 2018

Similar Items

Characterizing mortality in patients with AQP4‐Ab + neuromyelitis optica spectrum disorder
by: Francis, A, et al.
Published: (2024)

The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis
by: Messina, S, et al.
Published: (2021)

Features of the diagnosis and treatment of patients with AQP-4-positive neuromyelitis optica and MOG antibody disease
by: V. E. Avdeeva, et al.
Published: (2021-11-01)

AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature
by: Antonio Luca Spiezia, et al.
Published: (2022-11-01)

Frequency of Aqp4-Ab in patients with neuromyelitis optica (Devic's syndrome) is higher than predicted by NMO-IgG testing
by: Jarius, S, et al.
Published: (2007)

Neuromyelitis optica spectrum disorders associated with AQP4-positive-cancer—A case series
by: Yinghui Duan, et al.
Published: (2022-12-01)

Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder
by: Eun Bin Cho, et al.
Published: (2024-03-01)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
by: Sato, D, et al.
Published: (2014)

LATE-ONSET AQP4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER – DOES IT CONCEAL A PARANEOPLASTIC SYNDROME?
by: Cristina Vlaicu, et al.
Published: (2023-10-01)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Pittock, S, et al.
Published: (2019)

Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder
by: Zhichao Li, et al.
Published: (2023-01-01)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
by: Kezuka, T, et al.
Published: (2014)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
by: Sato, D, et al.
Published: (2014)

Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report
by: Xiaojing Li, et al.
Published: (2023-10-01)

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Nour, M, et al.
Published: (2015)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
by: Matthews, L, et al.
Published: (2013)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
by: Matthews, L, et al.
Published: (2014)

Neuromyelitis optica spectrum disorder
by: Simon Broadley, et al.
Published: (2017-09-01)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
by: Collongues, N, et al.
Published: (2013)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
by: Kim, W, et al.
Published: (2012)

Racial differences in neuromyelitis optica spectrum disorder
by: Kim, S, et al.
Published: (2018)

Treatment of Neuromyelitis Optica Spectrum Disorders
by: Koon-Ho Chan, et al.
Published: (2021-08-01)

Relapsing neuromyelitis optica spectrum disorder
by: M Lakshmi Lavanya, et al.
Published: (2021-01-01)

The evolving clinical spectrum of neuromyelitis optica
by: Viegas, S, et al.
Published: (2008)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
by: Downer, J, et al.
Published: (2012)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
by: Downer, J, et al.
Published: (2012)

Oily fish and raw vegetable consumption can decrease the risk of AQP4-positive neuromyelitis optica spectrum disorders: a Mendelian-randomization study
by: Shengnan Wang, et al.
Published: (2023-06-01)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
by: Nour, M, et al.
Published: (2014)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
by: Kitley, J, et al.
Published: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
by: Kitley, J, et al.
Published: (2013)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
by: Kitley, J, et al.
Published: (2013)

Case report: Granzyme-B expression by T- and B- cells during severe AQP4-positive Neuromyelitis Optica spectrum disorder with fatal venous thromboembolism outcome
by: Vinícius Oliveira Boldrini, et al.
Published: (2023-08-01)

Cell-based assay for anti-AQP4 antibody in Korean patients with neuromyelitis optica
by: Kim, B, et al.
Published: (2010)

Neuromyelitis optica spectrum disorders in pediatric patients
by: Yu. V. Tokareva, et al.
Published: (2018-04-01)

Possibilities of therapy for neuromyelitis optica spectrum disorders
by: E. S. Novikova
Published: (2022-01-01)

Editorial: Advances in neuromyelitis optica spectrum disorders
by: Yu Cai, et al.
Published: (2022-08-01)

Immunoadsorption in patients with neuromyelitis optica spectrum disorder
by: Simon Faissner, et al.
Published: (2016-07-01)

Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply.
by: Kitley, J, et al.
Published: (2014)

Anti-aquaporin 4 antibody-positivity of Korean patients with neuromyelitis optica spectrum disorders
by: Min, J, et al.
Published: (2010)

THE ASSOCIATION OF TWO RARE NEUROLOGICAL DISEASES: A MULTICENTRE STUDY OF 16 PATIENTS WITH ACHR ANTIBODY MYASTHENIA GRAVIS AND AQP4 ANTIBODY NEUROMYELITIS OPTICA SPECTRUM DISORDER
by: Leite, M, et al.
Published: (2012)